歐菲光(002456.SZ):公司3D ToF 方案廣泛應用於手機、車載、機器人、 AR/VR、 IoT 等領域
格隆匯11月21日丨歐菲光(002456.SZ)在投資者互動平台表示,公司 3D ToF 方案廣泛應用於手機、車載、機器人、 AR/VR、 IoT 等領域。公司微電子團隊2019年進入機器人賽道,推出ToF避障模塊。2024年推出雙光源ToF專利架構方案,實現“避障+定位導航技術”、10米探測距離、低功耗、高採樣率、低算力等優勢。由於公司與客户簽署了保密協議,無法披露與客户的供應關係,相關產品的供應情況請諮詢終端品牌或參考公開信息,敬請諒解。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.